International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7858068
Original Article
Thyroid Screening of Preterm and Term Newborn Discharged from SNCU
 ,
 ,
 ,
 ,
Published
April 24, 2023
Abstract
Background: The TSH and T4 level rises in 24 hours and decline gradually to 4 weeks of age and stabilizes at slightly at higher level than the adult in term newborns. In the preterm T4 level decline profoundly after birth resulting in hypothyroxemia of prematurity most marked in infants born prior to 30 weeks gestation. There is also in delay rise of TSH. Aims and Objections: To do thyroid screening preterm and term newborns babies admitted and later discharged from Special Newborn Care Unit. Material and Methods: This study was conducted from 2022 in Department of Pediatrics, Kamla Raja Hospital, G.R.M.C., Gwalior. Setting: Department of Pediatrics, SNCU, KRH in GRMC, Gwalior. Study design: Prospective cohort study. Sample size:120 newborns (60term and 60 preterm). Duration of study: 2 years. Statistical analysis: SPSS version 25. Results and Conclusion: 120 newborns (60 term and 60 preterm) were taken. Out of 60 preterms, 40 (66.66%) males and 20 (33.3%) females while 32 (53.3%) males and 28 (46.7%) were female term newborns. In the study, 2 preterm (1.67%) were having true congenital hypothyroidism and delay TSH rise was reported 3 preterm (5.1%) and 2 (3.3%) term newborn. In the study 3(5%) preterm and 2(3.33%) term newborn were having congenital hypothyroidism on admission but on second and third screening their thyroid becomes normal. So they were level as transient hypothyroidism. No case of congenital hypothyroidism in term newborn.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
1574 Views
251 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved